rss
J Clin Pathol doi:10.1136/jclinpath-2011-200442
  • Original article

The utility of a novel antibody in the pathological diagnosis of pancreatic acinar cell carcinoma

  1. Hirohisa Yano1
  1. 1Department of Pathology, Kurume University School of Medicine, Kurume, Japan
  2. 2Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, Fukuoka, Japan
  3. 3Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
  4. 4Department of Pathology, Saga Medical School, Faculty of Medicine, Saga University, Saga, Japan
  5. 5Division of Histopathology, Omuta City General Hospital, Omuta, Japan
  6. 6Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
  1. Correspondence to Dr Jun Akiba, Department of Pathology, Kurume University of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan; akiba{at}med.kurume-u.ac.jp
  1. Contributors Makiko Yasumoto have a central role in immunohistochemical staining and these assessment. Jun Akiba and Sachiko Ogasawara led immunohistochemical staining and these assessment. Masato Hamabashiri, Aya Daicho and Manabu Nakashima participated in the process of establishing this novel antibody. Fumio Yamasaki and Kazuhide Shimamatsu were provided specimens of the pancreatic tumors. Yusuke Ishida, Ryohei Kaji and Yoshinobu Okabe were provided samples, such as pancreatic juice etc. Yoshiki Naito, Tomoki Taira, Masamichi Nakayama, Osamu Nakashima and Koichi Ohshima participated in immunohistochemical staining. Michio Sata and Hirohisa Yano organized this mamanuscript.

  • Accepted 16 November 2011
  • Published Online First 7 January 2012

Abstract

Aims Acinar cell carcinomas (ACCs) are rare tumours of the exocrine pancreas accounting for about 1–2% of all pancreatic neoplasms in adults. It is therefore difficult to come across a large number of ACC cases in a single medical institution, and only a few serial studies have been published. Since ACCs present a wide variety of morphological patterns, immunohistochemical analysis is useful. In this study, the authors established a novel monoclonal antibody 2P-1-2-1 by means of a subtractive immunisation method.

Methods Immunohistochemical staining was performed using 50 primary pancreatic tumors, including 7 ACCs, 7 neuroendocrine tumours (NETs), 5 solid-pseudopapillary neoplasms (SPNs), and 31 ductal carcinomas and organs other than the pancreas.

Results Non-neoplastic acinar cells were stained diffusely, but epithelial cells of the pancreatic duct and the islets of Langerhans were not stained. In pancreatic tumours, all the seven ACCs were diffusely positive for the 2P-1-2-1 antibody. However, no positive staining was found in other pancreatic tumours including NETs, SPNs and ductal adenocarcinomas. The sensitivity and specificity of the 2P-1-2-1 antibody for ACCs were both 100%. In other organs studied, positive staining was observed only in the ectopic pancreas.

Conclusions It was shown that the 2P-1-2-1 antibody specifically stained the pancreatic acinar cells and tumours of acinar cell origin, such as ACCs. Although it remains unclear at this time to which proteins the monoclonal antibody 2P-1-2-1 is directed, it is suggested to be useful for the pathological diagnosis of ACCs and for the exclusion of other pancreatic tumours.

Footnotes

  • Funding This work was supported by the Japan Society for the Promotion of Science (JPSP) KAKENHI (Grant-in-Aid Challenging Exploratory Research: 21659151).

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was approved by the ethical committee of Kurume University (09034).

  • Provenance and peer review Not commissioned; externally peer reviewed.


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article